Dayvigo FDA Approval History
FDA Approved: Yes (First approved December 20, 2019)
Brand name: Dayvigo
Generic name: lemborexant
Dosage form: Tablets
Company: Eisai Inc.
Treatment for: Insomnia
Last updated by Judith Stewart, BPharm on Jan 27, 2021.
Dayvigo (lemborexant) is dual orexin receptor antagonist (DORA) for the treatment of insomnia.
Development timeline for Dayvigo
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.